🎈 Up Big Today: Find today's biggest gainers with our free screenerTry Stock Screener

Novocure stock jumps on positive trial results for cancer therapy

Published 02/12/2024, 11:28 pm
© Reuters.
NVCR
-

On Monday, Novocure (NASDAQ: NVCR) experienced a significant surge in stock price, climbing 19%, following the announcement of successful results from its Phase 3 PANOVA-3 clinical trial. The trial, which focused on the company's Tumor Treating Fields (TTFields) therapy for pancreatic cancer, met its primary endpoint by showing a statistically significant improvement in overall survival for patients with unresectable, locally advanced pancreatic adenocarcinoma when treated with TTFields in conjunction with gemcitabine and nab-paclitaxel.

The PANOVA-3 trial's positive outcome is a milestone for Novocure, as it marks the first Phase 3 trial to demonstrate a statistically significant benefit in overall survival specifically in unresectable, locally advanced pancreatic cancer. This is also Novocure's third positive Phase 3 clinical trial result within the last two years. The company has expressed its intention to seek regulatory approvals in the U.S., EU, Japan, and other key markets based on these findings.

Patients involved in the intent-to-treat population of the trial showed a median overall survival (mOS) of 16.20 months when treated with the TTFields therapy, compared to 14.16 months for those who received the standard treatment without TTFields, representing a 2.0-month improvement. This result was supported by a 13% improvement in the overall survival rate at 12 months and a 33% improvement at 24 months. The safety profile of TTFields therapy was consistent with prior clinical studies, indicating that it was well-tolerated by patients.

The full results from the PANOVA-3 trial are expected to be presented at an upcoming medical congress, offering the medical community a comprehensive look at the data. The anticipation for these results is high, as the trial represents a potential advancement in the treatment of a particularly challenging form of cancer.

In addition to the PANOVA-3 trial, Novocure is conducting the Phase 2 PANOVA-4 trial, which is investigating TTFields therapy in combination with atezolizumab, gemcitabine, and nab-paclitaxel for the treatment of metastatic pancreatic cancer. The PANOVA-4 trial has completed enrollment, and its data is anticipated to be released in 2026.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.